Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Nanomedicine (Lond). 2012 Oct 17;8(5):687–698. doi: 10.2217/nnm.12.134

Figure 1.

Figure 1

Schematic showing the strategy of co-encapsulation of irinotecan and cisplatin in a single nanoparticle targeted to PSMA receptors in prostate cancer cells. Once internalized, NPs co-deliver irinotecan and cisplatin to enable synergistic toxicity.